U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Porter Regional Hospital 2. 85 East U. S. Highway 6 Valparaiso, Indiana 46383			3. L	In accordance with application dated June 21, 2013, 3. License No. 13-17073-01 is renewed in its entirety to read as follows: 4. Expiration Date: November 30, 2023					
				Docket No. 030-12 Reference No.	150				
	oduct, source, and/or special nuclear erial	7. Che	mical and/or phy	rsical form	may	imum amount the possess at any er this license			
A.	Any byproduct material permitted by 10 CFR 35.100	Α.	Any Same		Α.	As needed			
B .	Any byproduct material permitted by 10 CFR 35.200	В.	Any		В.	As needed	Angel Away		
C.	Any byproduct material permitted by 10 CFR 35.300	C.	Any		C.	2 curies	The second second		
D.	Iridium-192 permitted by 10 CFR 35.400	D.	Sealed sour Medical Inte Model 81-0	rnational, Inc.,	D.	2 curies			
E. ³	lodine-125 permitted by 10 CFR 35.400	E.	Sealed sour Brachythera STM 1251)	ces (Bard py, Inc., Model	. ** E.	2 curies			
F.	Yttrium-90 permitted by 10 CFR 35.1000	F.	Sealed sour Medical Lim Spheres [®] m	•	F.	2 curies			

9. Authorized Use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE	2	of	3	PAGES
	MATERIALS LICENSE SUPPLEMENTARY SHEET	License No. 13-17073-01					
		Docket or Reference No. 030-12150					
		Amendment No. 46					

- E. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
- F. For medical use as permitted by 10 CFR 35.1000, in a Sirtex Medical Limited brachytherapy afterloader delivery system.

CONDITIONS

- 10. A. Licensed material in Subitems 6.A. through 6.F. may be used at the licensee's facilities located at 85 East U.S. Highway 6, Valparaiso, Indiana.
 - B. Licensed material in Subitems 6.A. and 6.B. may be used at the licensee's facilities located at 1505 South Calumet, Chesterton, Indiana.
- 11. The Radiation Safety Officer (RSO) for this license is James M. Forde, M.D.
- 12. Licensed material is only authorized for use by, or under the supervision of:
 - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
 - B. The following individuals are authorized users for medical uses:

Authorized User	Material and Use
Amjad Alkadri, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.1000 (limited to yttrium-90 as SIR-Spheres [®]).
Keith Atassi, M.D.	10 CFR 35.200.
Maximo V. Bleza, D.O.	10 CFR 35.100, 35.200, and 35.300.
John A. Forchetti, M.D.	10 CFR 35.100 and 35.200.
James M. Forde, M.D.	10 CFR 35.100, 35.200, and 35.300.
Jeffrey M. Huth, M.D.	10 CFR 35.100 and 35.200.
Anil Kothari, M.D.	10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities of 33 millicuries or less).
Esther Lee, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the use of iodine-131).

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMM	MISSION		PAGE	3	of	3	PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET		License No. 13-17073-01						
		Docket or Reference No. 030-12150						
		Amendment No. 46						
Authorized User M		Material a	and Use					

Hector J. Marchand, M.D.

10 CFR 35,200.

Vivek Mishra, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the use of iodine-131), and 35.1000 (limited to yttrium-90 as SIR-Spheres[®]).

Jeffrey Jon Quackenbush, M.D.

10 CFR 35.300 and 35.400.

Koppolu P. Sarma, M.D.

10 CFR 35.400.

Sandeep Sehgal, M.D.

10 CFR 35.200.

Michael Wheat, M.D.

10 CFR 35.200.

- 13. The licensee may transport licensed material in accordance with the provisions of 10 CFR Part 71 "Packaging and Transportation of Radioactive Materials."
- 14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U. S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
 - A. Application dated June 21, 2013 (with cover letter dated June 3, 2013, and excluding delegation of authority for A. Devata).

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date NOV 2 1 2013

Ву ___

Bryan A. Parker

Materials Licensing Branch

Region III